Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 4/2009

01.04.2009 | Original Paper

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy

verfasst von: Shin Nishio, Noriyuki Katsumata, Koji Matsumoto, Hiroshi Tanabe, Kan Yonemori, Tsutomu Kouno, Chikako Shimizu, Masashi Ando, Toshiharu Kamura, Takahiro Kasamatsu, Yasuhiro Fujiwara

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Limited information is available regarding the usefulness of third-line chemotherapy for recurrent ovarian, fallopian tube, and primary peritoneal cancer treated with platinum-taxane regimens as first-line therapy.

Patients and methods

We retrospectively reviewed the medical records of women with ovarian, fallopian tube, and primary peritoneal cancer who were treated at the National Cancer Center Hospital between 1999 and 2005 to investigate the relations of clinicopathological factors to important clinical endpoints such as the response rate (RR), time to progression (TTP) and overall survival (OS) after third-line chemotherapy.

Results

A total of 172 patients received first-line platinum/taxane regimens during the study period, among whom 111 had disease progression after first-line chemotherapy. Eighty-one of these 111 patients received second-line chemotherapy, and 73 had disease progression. Fifty-four of the 73 patients with disease progression received third-line chemotherapy. The RR to third-line chemotherapy was 40.7% (95% CI, 27.6–53.8%). The median TTP was 4.4 months (range 0–19.5 months), and the median OS was 10.4 months (range 1.5–44.3 months). Performance status (PS) and primary drug-free interval (DFI) were independent predictive factors for the RR to third-line chemotherapy (P = 0.04 and P = 0.009). PS and primary DFI were also independent predictive factors for TTP and OS on multivariate analysis (P = 0.006, = 0.005 and P = 0.01, = 0.004, respectively).

Conclusions

PS and primary DFI are useful predictors of the response to third-line chemotherapy in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. In this setting, however, both of these variables are subject to several well-established potential biases and limitations; further prospective studies are thus needed.
Literatur
Zurück zum Zitat Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650–653PubMed Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650–653PubMed
Zurück zum Zitat Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21:149s–167sPubMedCrossRef Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21:149s–167sPubMedCrossRef
Zurück zum Zitat Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC (2002) Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 86:200–211PubMedCrossRef Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC (2002) Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 86:200–211PubMedCrossRef
Zurück zum Zitat Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266–1274PubMed Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266–1274PubMed
Zurück zum Zitat Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8:963–968PubMedCrossRef Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8:963–968PubMedCrossRef
Zurück zum Zitat Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J, Holzel D (2002) Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 38:2435–2445PubMedCrossRef Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J, Holzel D (2002) Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 38:2435–2445PubMedCrossRef
Zurück zum Zitat Findley MK, Lee H, Seiden MV, Shah MA, Fuller AF, Goodman A, Penson RT (2005) Do more lines of chemotherapy make you live longer? Treatment for ovarian cancer comparing cohorts of patients 1989-90 with 1995-6 in multivariate analysis of survival. J Clin Oncol 23(Suppl):16S Findley MK, Lee H, Seiden MV, Shah MA, Fuller AF, Goodman A, Penson RT (2005) Do more lines of chemotherapy make you live longer? Treatment for ovarian cancer comparing cohorts of patients 1989-90 with 1995-6 in multivariate analysis of survival. J Clin Oncol 23(Suppl):16S
Zurück zum Zitat Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B (2002) Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum—a systematic review of the evidence from randomized trials. Eur J Gynaecol Oncol 23:104–110PubMed Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B (2002) Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum—a systematic review of the evidence from randomized trials. Eur J Gynaecol Oncol 23:104–110PubMed
Zurück zum Zitat Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51:15–36PubMedCrossRef Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51:15–36PubMedCrossRef
Zurück zum Zitat Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S (2001) Carcinoma of the ovary. J Epidemiol Biostat 6:107–138PubMed Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S (2001) Carcinoma of the ovary. J Epidemiol Biostat 6:107–138PubMed
Zurück zum Zitat Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics 2003. CA Cancer J Clin 53:5–26PubMedCrossRef Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics 2003. CA Cancer J Clin 53:5–26PubMedCrossRef
Zurück zum Zitat Markman M (1998) ‘‘Recurrence within 6 months of platinum- therapy’’: an adequate definition of ‘‘platinum-refractory’’ ovarian cancer? Gynecol Oncol 69:91–92PubMedCrossRef Markman M (1998) ‘‘Recurrence within 6 months of platinum- therapy’’: an adequate definition of ‘‘platinum-refractory’’ ovarian cancer? Gynecol Oncol 69:91–92PubMedCrossRef
Zurück zum Zitat Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393PubMed Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393PubMed
Zurück zum Zitat Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1998) Evidence that a ‘‘treatment-free interval of less than 6 months’’ does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol 124:326–328PubMedCrossRef Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1998) Evidence that a ‘‘treatment-free interval of less than 6 months’’ does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol 124:326–328PubMedCrossRef
Zurück zum Zitat Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141PubMed Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141PubMed
Zurück zum Zitat Rocconi RP, Case AS, Staughn JM Jr, Estes JM, Partridge EE (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effective analysis. Cancer 107:536–543PubMedCrossRef Rocconi RP, Case AS, Staughn JM Jr, Estes JM, Partridge EE (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effective analysis. Cancer 107:536–543PubMedCrossRef
Zurück zum Zitat Tangjitgamol S, See HT, Manusirvithaya S, Levenback CF, Gershenson DM, Kavanagh JJ (2004) Third-line chemotherapy in platinum-and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Cancer 12:804–814CrossRef Tangjitgamol S, See HT, Manusirvithaya S, Levenback CF, Gershenson DM, Kavanagh JJ (2004) Third-line chemotherapy in platinum-and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Cancer 12:804–814CrossRef
Zurück zum Zitat Thigpen JT, Vance RB, Khansur T (1993) Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71:1559–1564PubMed Thigpen JT, Vance RB, Khansur T (1993) Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71:1559–1564PubMed
Zurück zum Zitat Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 12:1748–1753PubMed Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 12:1748–1753PubMed
Zurück zum Zitat Villa A, Parazzini F, Scarfone G, Guarnerio P, Bolis G (1999) Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients. Br J Cancer 79:373–374PubMed Villa A, Parazzini F, Scarfone G, Guarnerio P, Bolis G (1999) Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients. Br J Cancer 79:373–374PubMed
Zurück zum Zitat Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, Peterson G, Markman M (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126–3129PubMed Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, Peterson G, Markman M (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126–3129PubMed
Metadaten
Titel
Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy
verfasst von
Shin Nishio
Noriyuki Katsumata
Koji Matsumoto
Hiroshi Tanabe
Kan Yonemori
Tsutomu Kouno
Chikako Shimizu
Masashi Ando
Toshiharu Kamura
Takahiro Kasamatsu
Yasuhiro Fujiwara
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0488-x

Weitere Artikel der Ausgabe 4/2009

Journal of Cancer Research and Clinical Oncology 4/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.